[1] Bajaj JS,O'Leary JG,Reddy KR,et al.Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures.Hepatology,2014, 60(1):250-255. [2] Jalan R,Saliba F,Pavesi M,et al.Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol,2014,61(5):1038-1047. [3] 张野, 聂青和.1892例肝衰竭患者并发症及死亡原因分析.实用肝脏病杂志, 2014,16(2):129-132. [4] Birkenfeld AL, Shulman GI.Nonalcoholic fatty liver disease, hepatic insulin resistance,and type 2 diabetes.Hepatology,2014, 59(2):713-736. [5] Liu YL, Patman GL, Leathart JB, et al.Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.J Hepatol,2014, 61(1):75-81. [6] Liu Y L, Reeves H L, Burt A D, et al.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. N Communications, 2014, 5(4):4309-4309. [7] 刘菲菲,吴吉圆,张海月,等.慢加急性乙型肝炎肝衰竭临床特征及血浆置换治疗对其预后的影响.实用肝脏病杂志.2016,19(2):188-191. [8] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.实用肝脏病杂志,2013,16(3):210-216. [9] Loomba R,Wolfson T,Ang B,et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease:A prospective study.Hepatology,2014,60(6):1920-1928. [10] Bandiera S,Pfeffer S,Baumert TF,et al.miR-122 A key factor and therapeutic target in liver disease. J Hepatol,2015,62(2):448-457. [11] 阮承兰, 张骏飞, 宋海燕,等.肝衰竭预后影响因素的Logistic回归分析. 中华疾病控制杂志, 2014, 18(6):537-540. |